Kiniksa Pharmaceuticals, Ltd. provided revenue guidance for 2023. Kiniksa now expects 2023 ARCALYST net product revenue of between $220 million and $230 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.77 USD | -1.69% | +1.23% | +12.71% |
05-14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
04-23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.71% | 1.43B | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023